Provider Briefing: Sronyx 28 Day Is No Longer Available

If your patients have been calling about Sronyx 28 Day, here's the short version: Mayne Pharma discontinued the product in early 2025, and remaining stock has been fully depleted. This is not a temporary shortage — it's a permanent market withdrawal.

This post provides a clinical overview for prescribers managing patients who need to transition off Sronyx, including equivalent alternatives, cost considerations, and practical tools for your workflow.

Timeline of the Sronyx 28 Day Discontinuation

Here's what happened and when:

• Late 2024: Patients and pharmacies began reporting difficulty sourcing Sronyx 28 Day. Wholesaler backorder notices appeared, but the situation was initially treated as a routine supply disruption.
• Early 2025: Mayne Pharma confirmed the discontinuation of Sronyx. The company stopped manufacturing and ceased distribution of the product.
• Mid-2025: Remaining pharmacy inventory was depleted. Sronyx became effectively unavailable nationwide.
• 2026: No supply exists. No resumption of manufacturing has been announced. Patients presenting with Sronyx prescriptions require a therapeutic substitution.

Prescribing Implications

Sronyx 28 Day contained levonorgestrel 0.1 mg / ethinyl estradiol 0.02 mg in a monophasic 21/7 regimen. It was a low-dose combined oral contraceptive (COC) and a generic of the discontinued brand Alesse.

Key Clinical Considerations

• Therapeutic equivalence: Multiple FDA-approved generics contain the identical active ingredients at identical doses. Switching between these products is clinically straightforward.
• Patient anxiety: Many patients have been on Sronyx for years and may express concern about switching. Reassurance that the active ingredients are identical can help ease the transition.
• Inactive ingredient sensitivity: In rare cases, patients may report differences in tolerability due to variations in inactive ingredients (fillers, dyes, binders). If a patient reports new symptoms after switching, consider trying a different manufacturer.
• Breakthrough bleeding: Some patients experience transient spotting when switching between equivalent formulations. This typically resolves within 1-2 cycles and does not indicate reduced efficacy.

Current Availability Picture

The following levonorgestrel 0.1 mg / ethinyl estradiol 0.02 mg products remain on the market as of early 2026:

• Vienva (Exeltis) — widely available
• Aubra (Afaxys) — broadly distributed
• Lutera (Mayne Pharma) — verify availability, same manufacturer as Sronyx
• Aviane (Teva) — one of the most commonly stocked generics
• Falmina (Novel Laboratories) — available at many pharmacies
• Larissia (Northstar Rx) — another available option
• Orsythia (Qualitest/Endo) — available at select pharmacies

For patients who need assistance locating these alternatives, Medfinder for Providers offers pharmacy availability data that can be integrated into clinical workflows.

Cost and Access Considerations

Insurance Coverage

Under the ACA contraceptive mandate, most commercial insurance plans cover at least one generic COC at $0 cost-sharing. However, plans may designate a "preferred" generic, and patients switching from Sronyx may need their new prescription aligned to the plan's formulary. If a patient encounters a copay, a formulary exception request or prior authorization may resolve it.

Uninsured / Underinsured Patients

For patients paying cash:

• Retail price: $40–$70 per 28-day pack for most levonorgestrel/EE generics
• With discount cards: $15–$25 per pack via GoodRx, SingleCare, or RxSaver
• Patient assistance: Title X clinics, Planned Parenthood, and state family planning programs offer low-cost or free contraceptives
• 340B pharmacies: Federally qualified health centers and eligible entities may offer deeply discounted pricing

For a patient-facing resource on cost savings, consider sharing our guide on saving money on Sronyx alternatives.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder's provider portal allows you to check real-time pharmacy availability for specific medications. This can help your team identify which pharmacies near your patients have the alternative in stock before writing the prescription, reducing callback volume and patient frustration.

Prescribing Tips

• Write for the generic name: Prescribing "levonorgestrel/ethinyl estradiol 0.1 mg/0.02 mg tablets" rather than a specific brand gives the pharmacy flexibility to dispense whichever equivalent they have in stock.
• Avoid DAW (Dispense as Written): Since Sronyx is discontinued, a DAW designation will result in the prescription going unfilled. Ensure substitution is permitted.
• Specify alternatives: If your EHR requires a brand selection, note in the comments that therapeutic equivalents are acceptable.
• Proactive outreach: If your practice has a significant number of Sronyx patients, consider a batch notification (patient portal message, phone call) informing them of the change and offering prescription updates.

Patient Education Resources

Share these articles with patients who have questions:

• Alternatives to Sronyx 28 Day
• Sronyx shortage update for patients
• What is Sronyx 28 Day?

Looking Ahead

There is no indication that Mayne Pharma or any other manufacturer plans to reintroduce Sronyx to the market. The generic low-dose COC space remains competitive, and multiple equivalent products are available. The primary challenge for providers is managing the transition for established patients — a process that is clinically straightforward but may require additional patient communication and follow-up.

If your practice manages a high volume of contraceptive patients, periodic monitoring of the oral contraceptive supply landscape is recommended. Resources like the ASHP Drug Shortage Resource Center and Medfinder for Providers can help you stay ahead of future disruptions.

Final Thoughts

The Sronyx 28 Day discontinuation is a permanent market change. Multiple therapeutically equivalent alternatives remain available, affordable, and well-tolerated. Proactive prescribing practices — writing for the generic name, avoiding DAW, and leveraging availability tools — can minimize disruption for your patients and your workflow.

For a complementary provider guide on helping patients locate stock, see our post on how to help your patients find Sronyx 28 Day in stock.